A case of hypophosphatemic osteomalacia secondary to deferasirox therapy.

Abstract

Patients with β-thalassemia major require iron-chelation therapy to avoid the complication of iron overload. Until recently, deferoxamine (DFO) was the major iron chelator used in patients requiring chronic hypertransfusion therapy, but DFO required continuous subcutaneous therapy. The availability of deferasirox (Exjade®), an orally active iron chelator, over the past 4 years represented a necessary alternative for patients requiring chelation therapy. However, there have been increasing reports of proximal renal tubular dysfunction and Fanconi syndrome associated with deferasirox in the literature. We report a case of hypophosphataemic osteomalacia secondary to deferasirox therapy.

• Authors: Frances Milat, Phillip Wong, Peter J Fuller, Lillian Johnstone, Peter G Kerr, James C G Doery, Boyd J Strauss, Donald K Bowden
• Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (J Bone Miner Res) Vol. 27 Issue 1 Pg. 219-22 (Jan 2012) ISSN: 1523-4681 [Electronic] United States
• PMID: 21956684 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 American Society for Bone and Mineral Research.

Chemical References

• Benzoates
• Phosphates
• Triazoles
• Deferasirox

Topics

• Adult
• Benzoates (adverse effects)
• Bone Density (drug effects)
• Deferasirox
• Dose-Response Relationship, Drug
• Female
• Humans
• Hypophosphatemia (blood, chemically induced, complications)
• Lumbar Vertebrae (drug effects, physiopathology)
• Osteomalacia (blood, chemically induced, complications)
• Phosphates (blood)
• Triazoles (adverse effects)